Table 1.
p53 expression status and its association with clinicopathological features
| p53 expression group | P value | P value (1 vs 0, 2, and 3) | ||||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | |||
| Sex | 0.089 | 0.074 | ||||
| Male | 70 (14.3) | 117 (23.9) | 66 (13.5) | 79 (16.1) | ||
| Female | 33 (6.7) | 69 (14.1) | 18 (3.7) | 38 (7.8) | ||
| Age | 0.927 | 0.809 | ||||
| > 61 | 46 (9.4) | 91 (18.6) | 40 (8.2) | 58 (11.8) | ||
| ≤ 61 | 57 (11.6) | 95 (19.4) | 44 (9.0) | 59 (12.0) | ||
| Tumor differentiation | 0.174 | 0.008 | ||||
| Well | 2 (0.4) | 5 (1.0) | 0 (0) | 2 (0.4) | ||
| Moderate | 27 (5.5) | 38 (7.8) | 27 (5.5) | 32 (6.5) | ||
| Poor | 18 (3.7) | 72 (14.7) | 30 (6.1) | 31 (6.3) | ||
| Poorly cohesive | 35 (7.1) | 53 (10.8) | 15 (3.1) | 39 (8.0) | ||
| Others | 21 (4.3) | 18 (3.7) | 12 (2.4) | 13 (2.7) | ||
| Lauren classification | 0.168 | 0.052 | ||||
| Intestinal | 48 (9.8) | 58 (5.9) | 32 (6.5) | 46 (9.4) | ||
| Diffuse | 44 (9.0) | 99 (11.8) | 36 (7.3) | 56 (11.4) | ||
| Mixed | 11 (2.2) | 29 (5.9) | 16 (3.3) | 15 (3.1) | ||
| pT | 0.704 | 0.390 | ||||
| pT2 | 26 (5.3) | 44 (9) | 18 (3.7) | 26 (5.3) | ||
| pT3 | 38 (7.8) | 73 (14.9) | 31 (6.3) | 39 (8.0) | ||
| pT4a | 33 (6.7) | 63 (12.9) | 29 (5.9) | 49 (10.0) | ||
| pT4b | 6 (1.2) | 6 (1.2) | 6 (1.2) | 3 (0.6) | ||
| pN | 0.056 | 0.008 | ||||
| pN0 | 29 (5.9) | 72 (14.7) | 22 (4.5) | 25 (5.1) | ||
| pN1 | 12 (2.4) | 34 (6.9) | 18 (3.7) | 27 (5.5) | ||
| pN2 | 22 (4.5) | 30 (6.1) | 19 (3.9) | 21 (4.3) | ||
| pN3a | 26 (5.3) | 27 (5.5) | 18 (3.7) | 27 (5.5) | ||
| pN3b | 14 (2.9) | 23 (4.7) | 7 (1.4) | 17 (3.5) | ||
| pTNM | 0.407 | 0.090 | ||||
| IB | 16 (3.3) | 30 (6.1) | 7 (1.4) | 10 (2.0) | ||
| IIA | 13 (2.7) | 39 (8.0) | 12 (2.4) | 16 (3.3) | ||
| IIB | 11 (2.2) | 26 (5.3) | 21 (4.3) | 24 (4.9) | ||
| IIIA | 13 (2.7) | 27 (5.5) | 7 (1.4) | 12 (2.4) | ||
| IIIB | 18 (3.7) | 21 (4.3) | 14 (2.9) | 21 (4.3) | ||
| IIIC | 18 (3.7) | 23 (4.7) | 15 (3.1) | 22 (4.5) | ||
| IV | 14 (2.9) | 20 (4.1) | 8 (1.6) | 12 (2.4) | ||
| Lymphatic invasion | < 0.001 | < 0.001 | ||||
| Absent | 29 (5.9) | 93 (19.0) | 27 (5.5) | 31 (6.3) | ||
| Present | 74 (15.1) | 93 (19.0) | 57 (11.6) | 86 (17.6) | ||
| Venous invasion | 0.028 | 0.034 | ||||
| Absent | 66 (13.5) | 149 (30.4) | 61 (12.5) | 89 (18.2) | ||
| Present | 37 (7.6) | 37 (7.6) | 23 (4.7) | 28 (5.7) | ||
| Perineural invasion | 0.051 | 0.305 | ||||
| Absent | 56 (11.4) | 78 (15.9) | 42 (8.6) | 44 (9.0) | ||
| Present | 47 (9.6) | 108 (2.0) | 42 (8.6) | 73 (14.9) | ||
| MSI | < 0.001 | < 0.001 | ||||
| Stable | 86 (17.6) | 128 (2.4) | 71 (14.5) | 98 (20.0) | ||
| Low | 14 (2.9) | 13 (2.7) | 5 (1.0) | 16 (3.3) | ||
| High | 3 (0.6) | 45 (9.2) | 8 (1.6) | 3 (0.6) | ||
| EBV | < 0.001 | < 0.001 | ||||
| Absent | 102 (20.8) | 164 (33.5) | 74 (15.1) | 114 (23.3) | ||
| Present | 1 (0.2) | 22 (4.5) | 10 (2.0) | 3 (0.6) | ||
Percentages in parenthesis
MSI microsatellite instability, EBV Epstein–Barr virus